Overcoming CMC Challenges in Cell and Gene Therapy: Part I
In this Manufacturing Chemist article, Certara's Drs. Hien Anh Bruno and Deven Shah discuss the…
CertaraAugust 23, 2024
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa. — August 21, 2024 -- Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraAugust 21, 2024
Quantitative Systems Pharmacology (QSP) Modeling for Immunotherapy-induced Cytokine Release Syndrome
Quantitative Systems Pharmacology (QSP) Modeling for Immunotherapy-induced Cytokine Release Syndrome
Cytokine Release Syndrome Cytokine release syndrome (CRS) is an inflammatory immune reaction that clinically manifests…
CertaraAugust 20, 2024
Navigating New Terrain: The Impact of Evolving EU Regulations on Regulatory Affairs
Presentation Materials Don't miss Part 2 in the series Joint Advice on FDA/EMA Compliance…
CertaraAugust 20, 2024
Using Quantitative Systems Pharmacology (QSP) Modeling for Oncology Dose Optimization
The FDA’s Project Optimus initiative aims to reform dose optimization and selection for oncology therapies…
CertaraAugust 19, 2024
Automation in clinical trials: Why it’s essential for success
Many companies in the life sciences industry are slow to adopt new technologies. This is…
CertaraAugust 19, 2024
Subject Exposure in Aggregate Safety Reports & Common Issues
All new and existing drugs should be safe, effective, and efficacious for the treated populations.…
CertaraAugust 16, 2024
Optimizing Clinical Development: Saving Time and Costs
Strategic mechanistic modeling solutions help an immunoncology biotech accelerate their clinical development of novel therapeutics.
CertaraAugust 16, 2024
Certara Launches Phoenix™ Version 8.5 Drug Development Software
RADNOR, PA – August 15, 2024 - Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraAugust 15, 2024
